A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects
- PMID: 1576046
- PMCID: PMC1381273
- DOI: 10.1111/j.1365-2125.1992.tb04033.x
A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects
Abstract
1. This randomised double-blind placebo controlled crossover study in healthy normotensive males compared the haemodynamic and behavioural responses following single oral doses of moxonidine (200 micrograms), clonidine (200 micrograms) and placebo. 2. Both active drugs significantly reduced blood pressure as compared with placebo: on average (over the study day) by -5.6/-0.8 with moxonidine and by -13.3/-5.3 mm Hg with clonidine. The hypotensive effect of clonidine was significantly greater (95% CI 3.2-12.2). Heart rate was unchanged by either drug. 3. Psychomotor testing, salivary flow and side effect reporting showed a consistent treatment rank order similar to that of the hypotensive response: clonidine greater than moxonidine greater than placebo. 4. Although moxonidine produced less adverse effects than clonidine, an equivalent hypotensive response was not demonstrated in normal subjects. Further study at comparable antihypertensive doses is required to clarify the relative side effect profile of these agents.
Similar articles
-
I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.Drugs Aging. 2000 Aug;17(2):133-59. doi: 10.2165/00002512-200017020-00005. Drugs Aging. 2000. PMID: 10984201 Review.
-
Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function.J Cardiovasc Pharmacol. 1995;26 Suppl 2:S48-54. J Cardiovasc Pharmacol. 1995. PMID: 8642806 Clinical Trial.
-
Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits.J Pharmacol Exp Ther. 1996 Feb;276(2):411-20. J Pharmacol Exp Ther. 1996. PMID: 8632304
-
General pharmacology of the novel centrally acting antihypertensive agent moxonidine.Arzneimittelforschung. 1988 Oct;38(10):1426-34. Arzneimittelforschung. 1988. PMID: 3196383
-
Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.J Hum Hypertens. 1997 Aug;11 Suppl 1:S29-45. J Hum Hypertens. 1997. PMID: 9321737 Review.
Cited by
-
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.J Hypertens Suppl. 1997 Jan;15(1):S9-23. doi: 10.1097/00004872-199715011-00002. J Hypertens Suppl. 1997. PMID: 9050981 Free PMC article. Review.
-
Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.Pharmacol Ther. 2009 Aug;123(2):224-38. doi: 10.1016/j.pharmthera.2009.04.001. Epub 2009 Apr 23. Pharmacol Ther. 2009. PMID: 19393691 Free PMC article. Review.
-
Clinical experience with moxonidine.Cardiovasc Drugs Ther. 1994 Mar;8 Suppl 1:49-58. doi: 10.1007/BF00877084. Cardiovasc Drugs Ther. 1994. PMID: 8068579 Review.
-
I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.Drugs Aging. 2000 Aug;17(2):133-59. doi: 10.2165/00002512-200017020-00005. Drugs Aging. 2000. PMID: 10984201 Review.
-
Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.Drugs. 1999 Nov;58(5):799-812. doi: 10.2165/00003495-199958050-00003. Drugs. 1999. PMID: 10595861 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical